Loading...
•
Jun 30, 2022
TransMedics Q2 2022 Earnings Report
Accelerated commercial momentum led to net revenue of $20.5 million, and the 2022 revenue guidance range was raised to $67 million to $75 million.
Key Takeaways
TransMedics reported a 151% increase in net revenue for the second quarter of 2022, reaching $20.5 million. The growth was primarily driven by increased commercial sales of the OCS™ Heart and OCS™ Liver in the United States. The company also updated its full year 2022 net revenue guidance to be in the range of $67 million to $75 million.
Net revenue of $20.5 million in the second quarter of 2022, a 151% increase compared to the second quarter of 2021.
Transplant centers use of the National OCS Program (NOP) drove 84% of total US revenue.
Integrated OCS™ Heart DCD offering into NOP
Refinanced outstanding debt with new $60 million term loan
Forward Guidance
TransMedics is updating full year 2022 net revenue to be in the range of $67 million to $75 million, which represents 121% to 148% growth compared to the company’s prior year net revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...